NAD(P)+ transhydrogenase

ChromaDex to Host Symposium on NAD+ in Human Health and Disease at NUTRITION 2020 LIVE ONLINE Annual Meeting

Retrieved on: 
Monday, June 1, 2020

ChromaDex Corp. (NASDAQ:CDXC) announced today it has organized a virtual symposium entitled Nicotinamide Adenine Dinucleotide (NAD+) in Human Health and Disease: The State of the Science on Nutrition Interventions tomorrow Tuesday, June 2, from 8:30 to 10:00 AM EDT at NUTRITION 2020 LIVE ONLINE , the annual meeting hosted by the American Society for Nutrition (ASN).

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) announced today it has organized a virtual symposium entitled Nicotinamide Adenine Dinucleotide (NAD+) in Human Health and Disease: The State of the Science on Nutrition Interventions tomorrow Tuesday, June 2, from 8:30 to 10:00 AM EDT at NUTRITION 2020 LIVE ONLINE , the annual meeting hosted by the American Society for Nutrition (ASN).
  • We are pleased to continue the practice of making Niagen freely available to the nutrition research community through our industry leading ChromaDex External Research Program (CERP) .
  • The satellite program will focus on the latest findings on NAD+ and human health and disease and how maintaining or raising NAD+ levels contributes to resilience.
  • NUTRITION 2020 LIVE ONLINE is hosted by the American Society for Nutrition (ASN), the preeminent professional organization for nutrition research scientists and clinicians around the world.

ChromaDex Chief Scientific Advisor Dr. Charles Brenner Receives 2020 National Scientific Achievement Award from the American Society for Nutrition

Retrieved on: 
Thursday, May 21, 2020

Carver Chair and Head of Biochemistry at the University of Iowa and ChromaDex Chief Scientific Advisor, was named the 2020 recipient of the Mary Swartz Rose Senior Investigator Award from the American Society for Nutrition (ASN) and its Foundation.

Key Points: 
  • Carver Chair and Head of Biochemistry at the University of Iowa and ChromaDex Chief Scientific Advisor, was named the 2020 recipient of the Mary Swartz Rose Senior Investigator Award from the American Society for Nutrition (ASN) and its Foundation.
  • Dr. Brenner is one of the worlds foremost experts in nicotinamide adenine dinucleotide (NAD) research.
  • NR is also known as Niagen, a form of vitamin B3 exclusively licensed by ChromaDex.
  • The ASN and CRN will present Dr. Brenner as a featured speaker as part of Nutrition 2020 Live Online being held June 1 4, 2020.

Ninth Published Human Trial on Niagen® Nicotinamide Riboside (NR) Shows Increase in NAD+ Levels, Additional Research Highlights Downfalls of Nicotinamide Mononucleotide (NMN)

Retrieved on: 
Wednesday, May 6, 2020

Through its industry leading research program, called the ChromaDex External Research Program (CERP), ChromaDex provides its patented nicotinamide riboside (NR, or Niagen) ingredient to research institutions and universities at no cost.

Key Points: 
  • Through its industry leading research program, called the ChromaDex External Research Program (CERP), ChromaDex provides its patented nicotinamide riboside (NR, or Niagen) ingredient to research institutions and universities at no cost.
  • ChromaDex continues to support NAD+ research and through CERP has developed a global community of esteemed researchers exploring the potential Niagen and NAD+ can have on human health.
  • Newly published clinical research in the American Journal of Clinical Nutrition examined nicotinamide riboside supplementation at 1 gram per day for six weeks in healthy overweight or obese men.
  • Its flagship ingredient, NIAGEN nicotinamide riboside, sold directly to consumers as TRU NIAGEN , is backed with clinical and scientific research, as well as extensive IP protection.

Cellular Health Market Leader Tru Niagen® Launches Online in Australia

Retrieved on: 
Monday, March 23, 2020

Tru Niagen received its listing number on the Australian Registry of Therapeutic Goods (ARTG) on January 8, 2020 (AUST L 328365).

Key Points: 
  • Tru Niagen received its listing number on the Australian Registry of Therapeutic Goods (ARTG) on January 8, 2020 (AUST L 328365).
  • Tru Niagen is a breakthrough supplement to increase NAD+ (nicotinamide adenine dinucleotide) levels, help maintain general health and well-being, and support energy levels.
  • ChromaDex partnered with Matakana Health to launch Tru Niagen in New Zealand in September 2018 and recently expanded the partnership to include distribution rights in Australia.
  • We appreciate the robust science behind Tru Niagen and are happy to launch this product in Australia with the pioneers at ChromaDex.

Promoting Healthy Aging by Promoting Cellular Function: Quicksilver Scientific introduces NAD+ Gold™, a fast-acting tonic that boosts vitality in aging bodies

Retrieved on: 
Wednesday, December 4, 2019

Now the latest breakthrough product from Quicksilver Scientific , NAD+ Gold is designed to produce more NAD+ and thus promote healthy aging, cognition and metabolism, among an array of other benefits.

Key Points: 
  • Now the latest breakthrough product from Quicksilver Scientific , NAD+ Gold is designed to produce more NAD+ and thus promote healthy aging, cognition and metabolism, among an array of other benefits.
  • Delivering the tonic initially through the mucous membranes of the mouth via Quicksilver's state-of-the-art liposomal delivery technology greatly increases the tonic's efficiency and bioavailability.
  • NAD+ Gold is an effective way to potentially reduce the harmful effects of aging, including fatigue and a greater propensity to disease.
  • Research indicates that it may improve stamina and endurance, and promote brain health," said Dr. Christopher Shade, Founder & CEO, Quicksilver Scientific.

New Study Demonstrates a Unique Role of Nicotinamide Riboside Over Other NAD Precursors

Retrieved on: 
Thursday, October 17, 2019

The study investigated the impact on the liver when its cells lose the ability to use the nutrient nicotinamide riboside (NR).

Key Points: 
  • The study investigated the impact on the liver when its cells lose the ability to use the nutrient nicotinamide riboside (NR).
  • It is also the first study to show the physiological consequences that arise when cells lose the ability to use NR.
  • In December 2018, ChromaDex entered into a license and supply agreement for NIAGEN (nicotinamide riboside) with Nestl Health Science, a global leader pioneering quality science-based nutritional health solutions.
  • This new study provides additional evidence that NR is physiologically distinct from other NAD precursors and may play a unique role in maintaining cellular health and resiliency in the face of metabolic stress.

New Cutting Edge Treatment Center, Klarity Life, Offers Alternative to Traditional Drug & Alcohol Detox Programs

Retrieved on: 
Wednesday, August 21, 2019

The innovative program, designed to treat those who may have failed traditional drug and detox programs, uses both intravenous infusions of drugs, Nicotinamide Adenine Dinucleotide (NAD+) and Ketamine to contribute to a nearly painless and fast acting detox.

Key Points: 
  • The innovative program, designed to treat those who may have failed traditional drug and detox programs, uses both intravenous infusions of drugs, Nicotinamide Adenine Dinucleotide (NAD+) and Ketamine to contribute to a nearly painless and fast acting detox.
  • This customized program for each patient ensures a smooth transition to a life free from the grip of addiction by mediating stress response and traumatic memories.
  • Determined to change the landscape in America's rehabilitation industry, Hoffman and Liang collaborated again to open Klarity Life.
  • "While some programs focus on treating addiction itself, we focus on treating the person working to recover from the addiction.

ChromaDex Receives Positive Opinion on Nicotinamide Riboside as a Novel Food from the World-Leading European Food Safety Authority (EFSA)

Retrieved on: 
Wednesday, August 7, 2019

Safety is paramount for ChromaDex and this positive opinion from EFSA underscores our depth of science, and is the latest in a consistently positive series of reviews of NR by authoritative bodies, said ChromaDex CEORob Fried.

Key Points: 
  • Safety is paramount for ChromaDex and this positive opinion from EFSA underscores our depth of science, and is the latest in a consistently positive series of reviews of NR by authoritative bodies, said ChromaDex CEORob Fried.
  • We are diligently working to complete the regulatory process to bring NR to the health-conscious people of the EU.
  • Cells can use NR, commercially known as Niagen, to create nicotinamide adenine dinucleotide (NAD), which is an essential molecule found in every living cell.
  • Its flagship ingredient, NIAGEN nicotinamide riboside, sold directly to consumers as TRU NIAGEN , is backed with clinical and scientific research, as well as extensive IP protection.